Search Results - "Therapeutic approach"

The neurological symptoms of COVID-19

Table of Contents: “…Contents: Diversity and incidence of neurological symptoms attributable to COVID-19 -- Mechanisms by which SARS-CoV-2 infection triggers neurological symptoms -- Singularity of SARS-CoV-2, among coronaviruses, in triggering neurological symptoms -- Therapeutic approaches to prevent or improve neurological symptoms -- Incidence of psychiatric symptoms resulting from COVID-19 in a subset of patients -- Relationship between neurological and psychiatric symptoms.…”
Get full text
Series

The neurological symptoms of COVID-19

Table of Contents: “…Contents: Diversity and incidence of neurological symptoms attributable to COVID-19 -- Mechanisms by which SARS-CoV-2 infection triggers neurological symptoms -- Singularity of SARS-CoV-2, among coronaviruses, in triggering neurological symptoms -- Therapeutic approaches to prevent or improve neurological symptoms -- Incidence of psychiatric symptoms resulting from COVID-19 in a subset of patients -- Relationship between neurological and psychiatric symptoms.…”
Get full text
Series

Hepatic encephalopathy in cirrhosis a disorder of glial-neuronal signalling /

Table of Contents: “…Contents: Classification of hepatic encephalopathy -- Hepatic encephalopathy in cirrhosis -- Transjugular intrahepatic portosystemic shunt (TIPS) -- Hepatic encephalopathy post-TIPS -- Neuropathology of hepatic encephalopathy in chronic liver failure -- Cirrhosis-related Parkinsonism -- PET studies in cirrhosis -- Neuroinflammation and hepatic encephalopathy in cirrhosis -- Systemic inflammatory response syndrome (SIRS) in cirrhosis -- Translocator protein and hepatic encephalopathy in cirrhosis -- Modulatory site for neurosteroids -- Prevention and treatment of hepatic encephalopathy in cirrhosis -- Emerging new therapeutic approaches.…”
Get full text
Series

Hepatic encephalopathy in cirrhosis a disorder of glial-neuronal signalling /

Table of Contents: “…Contents: Classification of hepatic encephalopathy -- Hepatic encephalopathy in cirrhosis -- Transjugular intrahepatic portosystemic shunt (TIPS) -- Hepatic encephalopathy post-TIPS -- Neuropathology of hepatic encephalopathy in chronic liver failure -- Cirrhosis-related Parkinsonism -- PET studies in cirrhosis -- Neuroinflammation and hepatic encephalopathy in cirrhosis -- Systemic inflammatory response syndrome (SIRS) in cirrhosis -- Translocator protein and hepatic encephalopathy in cirrhosis -- Modulatory site for neurosteroids -- Prevention and treatment of hepatic encephalopathy in cirrhosis -- Emerging new therapeutic approaches.…”
Get full text
Series

Hepatic encephalopathy in cirrhosis a disorder of glial-neuronal signalling /

Table of Contents: “…Contents: Classification of hepatic encephalopathy -- Hepatic encephalopathy in cirrhosis -- Transjugular intrahepatic portosystemic shunt (TIPS) -- Hepatic encephalopathy post-TIPS -- Neuropathology of hepatic encephalopathy in chronic liver failure -- Cirrhosis-related Parkinsonism -- PET studies in cirrhosis -- Neuroinflammation and hepatic encephalopathy in cirrhosis -- Systemic inflammatory response syndrome (SIRS) in cirrhosis -- Translocator protein and hepatic encephalopathy in cirrhosis -- Modulatory site for neurosteroids -- Prevention and treatment of hepatic encephalopathy in cirrhosis -- Emerging new therapeutic approaches.…”
Get full text
Series

Therapy in cancer 2008 quo vadis? /

Table of Contents: “…Contents: Why pursuing new therapeutic approaches in cancer is important -- Prevention and screening -- Current cancer therapy: non-surgical -- Most chemotherapy targets DNA -- Chemotherapy effects -- Current state of cancer therapy: efficacy and toxicity -- Molecular pathogenesis of cancer -- Pursuing targeted therapy in cancers -- Targeted biologic therapies -- Evolving targets and agents -- Shift from chemotherapy to targeted agents -- Clinically established molecular targets in malignancies -- Targeted therapy: proteins and small molecules -- Changes brought about by targeting: efficacy and toxicity -- Biomarkers in drug development -- What is currently known: angiogenesis -- The VEGF family and its receptors -- Bevacizumab and Sorafenib -- Does toxicity correlate with response? …”
Get full text
Series

Therapy in cancer 2008 quo vadis? /

Table of Contents: “…Contents: Why pursuing new therapeutic approaches in cancer is important -- Prevention and screening -- Current cancer therapy: non-surgical -- Most chemotherapy targets DNA -- Chemotherapy effects -- Current state of cancer therapy: efficacy and toxicity -- Molecular pathogenesis of cancer -- Pursuing targeted therapy in cancers -- Targeted biologic therapies -- Evolving targets and agents -- Shift from chemotherapy to targeted agents -- Clinically established molecular targets in malignancies -- Targeted therapy: proteins and small molecules -- Changes brought about by targeting: efficacy and toxicity -- Biomarkers in drug development -- What is currently known: angiogenesis -- The VEGF family and its receptors -- Bevacizumab and Sorafenib -- Does toxicity correlate with response? …”
Get full text
Series

Therapy in cancer 2008 quo vadis? /

Table of Contents: “…Contents: Why pursuing new therapeutic approaches in cancer is important -- Prevention and screening -- Current cancer therapy: non-surgical -- Most chemotherapy targets DNA -- Chemotherapy effects -- Current state of cancer therapy: efficacy and toxicity -- Molecular pathogenesis of cancer -- Pursuing targeted therapy in cancers -- Targeted biologic therapies -- Evolving targets and agents -- Shift from chemotherapy to targeted agents -- Clinically established molecular targets in malignancies -- Targeted therapy: proteins and small molecules -- Changes brought about by targeting: efficacy and toxicity -- Biomarkers in drug development -- What is currently known: angiogenesis -- The VEGF family and its receptors -- Bevacizumab and Sorafenib -- Does toxicity correlate with response? …”
Get full text
Series